Short and long-term outcomes of minimally invasive central pancreatectomy: Comparison with minimally invasive spleenpreserving subtotal distal pancreatectomy
Executive Summary
This briefing document analyzes the clinical outcomes of Minimally Invasive Central Pancreatectomy (MI-CP) compared to Minimally Invasive Spleen-Preserving Subtotal Distal Pancreatectomy (MI-SpSTDP) for the treatment of benign and borderline pancreatic tumors. Based on a retrospective study of 59 patients at Severance Hospital, the analysis indicates that while MI-CP is a more complex procedure involving longer operation times and hospital stays, it is a safe and effective technique that superiorly preserves endocrine function.
Critical Takeaways:
Safety and Complications: There is no statistically significant difference in postoperative complications or clinically relevant Postoperative Pancreatic Fistula (POPF) between MI-CP and MI-SpSTDP.
Endocrine Function: MI-CP significantly reduces the risk of new-onset pancreatogenic diabetes mellitus (PDM) compared to MI-SpSTDP (4.3% vs. 25.0%).
Exocrine Function: Both procedures maintain stable nutritional status, with no significant differences in long-term exocrine function as measured by Controlling Nutritional Status (CONUT) scores.
Surgical Complexity: MI-CP requires significantly longer operative time (mean 362.3 minutes) compared to MI-SpSTDP (mean 256.3 minutes).
1. Study Overview and Methodology
The study compared two parenchymal-sparing techniques for tumors located in the neck or proximal body of the pancreas. Central pancreatectomy (CP) is traditionally considered more complex due to the creation of two pancreatic cut surfaces, which theoretically increases the risk of complications like POPF.
1.1 Study Population and Scope
Total Participants: 59 patients (12 male, 47 female).
Procedure Breakdown: 23 cases of MI-CP and 36 cases of MI-SpSTDP.
Timeframe: March 2007 to June 2020.
Inclusion Criteria: Benign or borderline malignant tumors (e.g., NET, SPT, IPMN). Patients with pre-existing diabetes were excluded to accurately measure new-onset PDM.
Surgical Approach: All procedures utilized minimally invasive techniques (laparoscopic or robotic).
1.2 Evaluation Metrics
Short-term: Operation time, blood loss, length of hospital stay, and complications (Clavien-Dindo classification).
Long-term: Endocrine function (new-onset DM and Impaired Fasting Glucose/IFG) and exocrine/nutritional status (CONUT scores based on albumin, cholesterol, and lymphocyte levels).
2. Comparative Analysis of Perioperative Outcomes
The data highlights distinct differences in the technical demands and immediate recovery phases of the two procedures.
2.1 Technical Complexity and Recovery
MI-CP is characterized by a significantly longer operative duration (approximately 106 minutes longer on average than MI-SpSTDP) and a longer hospital stay (an additional 5.5 days). These differences are attributed to the technical challenges of managing two pancreatic remnants and performing a pancreaticojejunostomy or pancreaticogastrostomy.
2.2 Safety Profile
Despite the increased complexity of MI-CP, the study found no statistical difference in the rate of major complications (Clavien-Dindo grade 3 or more) or the incidence of clinically relevant POPF (Grade B or C). This suggests that the advancement of minimally invasive techniques and perioperative management has mitigated the historical risks associated with central pancreatectomy.
3. Long-Term Functional Outcomes
The primary advantage of MI-CP over MI-SpSTDP lies in its ability to preserve functional pancreatic tissue, thereby maintaining metabolic health.
3.1 Endocrine Preservation (Diabetes Risk)
The preservation of the distal pancreas in MI-CP results in a markedly lower incidence of metabolic impairment:
New-onset PDM: Only 4.3% (1 case) in the MI-CP group compared to 25.0% (9 cases) in the MI-SpSTDP group (p = 0.039).
Impaired Fasting Glucose (IFG): 39.1% in the MI-CP group vs. 58.3% in the MI-SpSTDP group.
Onset Timing: Diabetes was diagnosed earlier in the subtotal distal pancreatectomy group.
3.2 Exocrine Function and Nutritional Status
Exocrine function was assessed using the CONUT score, which tracks nutritional markers. Both groups showed stability between preoperative and one-year postoperative assessments:
MI-CP CONUT Change: 0.74 ± 0.75 to 0.78 ± 0.99 (p = 0.803).
MI-SpSTDP CONUT Change: 0.86 ± 0.83 to 0.61 ± 0.59 (p = 0.071).
The results indicate that neither procedure leads to significant long-term nutritional deterioration, and patients can maintain appropriate nutritional status with standard postoperative measures.
4. Clinical Significance and Conclusions
The study concludes that for patients with benign or borderline tumors in the neck or proximal body of the pancreas, MI-CP should be the first option considered, particularly when long-term quality of life is a priority.
Key Arguments for MI-CP:
Superior Quality of Life: By preserving a greater volume of normal pancreatic parenchyma, MI-CP maintains a superior capacity for glucose metabolism.
Functional Integrity: It preserves both the spleen and the continuity of the gastrointestinal bile flow.
Feasibility of Minimally Invasive Approach: The robotic and laparoscopic approaches make CP a safe alternative to more radical resections, neutralizing historical concerns regarding excessive morbidity.
Final Assessment: While MI-SpSTDP remains a viable and faster surgical option, the significantly higher risk of postoperative diabetes (one in four patients) makes it a less desirable choice for patients with high life expectancy. MI-CP, despite its longer operative time and recovery period, offers a definitive advantage in avoiding long-term metabolic complications.
